Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

381 recalls, newest first

Class II · Moderate risk

Inflectra (infliximab-dyyb)

cGMP Deviations: Product intended for quarantine was inadvertently distributed.

Ongoing cGMP deviation McKesson NDC 0069-0809-01 D-0213-2025
Class II · Moderate risk

Liceout

CGMP violations.

Ongoing cGMP deviation Neogen Corporation D-0074-2025
Class II · Moderate risk

Liceout

CGMP violations.

Ongoing cGMP deviation Neogen Corporation D-0073-2025

Recalls by year